||Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 577 active entries
Kleine Präsidentenstr. 1
Phone: +49-30-24 34 5-0
Fax: +49-30-24 34 5-555
Stock symbol: ECX
Please notice: This entry hasn't been updated by the submitting company for more than 2 years. It could be possible that this company doesn't longer exists.
Epigenomics is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The Company’s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics’ lead product, Epi proColon®, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the U.S.A. The Company’s technology and products have been validated through multiple partnerships with leading global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an international company with operations in Europe and the U.S.A.For more information,please visit Epigenomics´website at www.epigenomics.com.
There are five equally important levels of information in a cell: genes, RNA, proteins, metabolism, and methylation. Methylation is a modification of one of DNA's four bases, namely cytosine, which normally occurs either with or without a methyl group attached. If a methyl group is attached to cytosine in the promotor region of a gene, the gene can in most cases not be activated by any transcription factors, thus not producing a protein. As each cell in the body contains the whole set of genes but uses only a subset according to its function, a wide range of genes need to be silenced by methylation. The methylation pattern is heritable through cell divisions and cannot only be correlated to different tissue types, but also to specific disease.
Epigenomics’ technologies used in its product development consists of genome-wide DNA Methylation discovery, , Bisulfite Sequencing, proprietary DNA methylation discovery, bisulfite sequencing, proprietary DNA methylation arrays, and sensitive methylation detection. These make the detection of DNA-methylation signals feasible and cost effective.
Epi proColon, a blood-based test for the early detection of colorectal cancer
Epi proLung, a confirmatory test that aids in the diagnosis of lung cancer
•Geert Walther Nygaard, CEO
•Dr. Thomas Taapken, CFO
•Prof Dr. Dr. Rolf Krebs, (Chairman), ex-Boehringer Ingelheim
•Prof Dr. Dr. Uwe Bicker
•Prof Dr. Guenther Reither
•Ann Clare Kessler, Ph.D.
•Joseph Anderson, Ph.D.
Number of Employees:86
Last update of this entry: September 21, 2011